A clinical trial of removal of bilirubin in blood by Evaflux-2A.
We performed both free and albumin-bound bilirubin removal therapy using the Evaflux-2A and evaluated its clinical effects. The removal rates of total bilirubin in the first and second sessions were 31.4%, and 31.0%, respectively. Our clinical data suggested that plasma exchange using Evaflux-2A and an albumin-added electrolyte solution as the substitute fluid was useful in the treatment of hyperbilirubinemia.
Hida
M
M
Department of Transplantation, School of Medicine, Tokai University, Japan.
Takamiya
T
T
Kitajima
N
N
Hiraga
S
S
Satoh
T
T
D001663:Bilirubin / Q000097:blood*; D006440:Hemofiltration / Q000379:methods; D006801:Humans; D006932:Hyperbilirubinemia / Q000097:blood / Q000628:therapy*; D046911:Macromolecular Substances; D008297:Male; D008875:Middle Aged; D010951:Plasma Exchange / Q000295:instrumentation*; D011145:Polyvinyls / Q000008:administration & dosage*
D046911:Macromolecular Substances; D011145:Polyvinyls; C020320:ethylene-vinyl alcohol copolymer; D001663:Bilirubin